Literature DB >> 21466787

Cytochrome P4504f, a potential therapeutic target limiting neuroinflammation.

Neha Sehgal1, Varsha Agarwal, Rupanagudi Khader Valli, Shanker Dutt Joshi, Leposava Antonovic, Henry W Strobel, Vijayalakshmi Ravindranath.   

Abstract

Inflammatory processes are involved in the pathogenesis and/or progression of acute central nervous system (CNS) infection, traumatic brain injury and neurodegenerative disorders among others indicating the need for novel strategies to limit neuroinflammation. Eicosanoids including leukotrienes, particularly leukotriene B(4) (LTB(4)) are principle mediator(s) of inflammatory response, initiating and amplifying the generation of cytokines and chemokines. Cytochrome P450 (Cyp), a family of heme proteins mediate metabolism of xenobiotics and endogenous compounds, such as eicosanoids and leukotrienes. Cytochrome P4504F (Cyp4f) subfamily includes five functional enzymes in mouse. We cloned and expressed the mouse Cyp4f enzymes, assayed their relative expression in brain and examined their ability to hydroxylate the inflammatory cascade prompt LTB(4) to its inactive 20-hydroxylated product. We then examined the role of Cyp4fs in regulating inflammatory response in vitro, in microglial cells and in vivo, in mouse brain using lipopolysacharide (LPS), as a model compound to generate inflammatory response. We demonstrate that mouse brain Cyp4fs are expressed ubiquitously in several cell types in the brain, including neurons and microglia, and modulate inflammatory response triggered by LPS, in vivo and in microglial cells, in vitro through metabolism of LTB(4) to the inactive 20-hydroxy LTB(4). Chemical inhibitor or shRNA to Cyp4fs enhance and inducer of Cyp4fs attenuates inflammatory response. Further, induction of Cyp4f expression lowers LTB(4) levels and affords neuroprotection in microglial cells or mice exposed to LPS. Thus, catalytic activity of Cyp4fs is a novel target for modulating neuroinflammation through hydroxylation of LTB(4).
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21466787     DOI: 10.1016/j.bcp.2011.03.025

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  Increase of 20-HETE synthase after brain ischemia in rats revealed by PET study with 11C-labeled 20-HETE synthase-specific inhibitor.

Authors:  Toshiyuki Kawasaki; Toshiyuki Marumo; Keiko Shirakami; Tomoko Mori; Hisashi Doi; Masaaki Suzuki; Yasuyoshi Watanabe; Shigeyuki Chaki; Atsuro Nakazato; Yukio Ago; Hitoshi Hashimoto; Toshio Matsuda; Akemichi Baba; Hirotaka Onoe
Journal:  J Cereb Blood Flow Metab       Date:  2012-06-06       Impact factor: 6.200

2.  Cytotoxic 1-deoxysphingolipids are metabolized by a cytochrome P450-dependent pathway.

Authors:  Irina Alecu; Alaa Othman; Anke Penno; Essa M Saied; Christoph Arenz; Arnold von Eckardstein; Thorsten Hornemann
Journal:  J Lipid Res       Date:  2016-11-21       Impact factor: 5.922

3.  Capillarisin Suppresses Lipopolysaccharide-Induced Inflammatory Mediators in BV2 Microglial Cells by Suppressing TLR4-Mediated NF-κB and MAPKs Signaling Pathway.

Authors:  Zhen Yu; Ling Tang; Lifen Chen; Jifang Li; Wanfu Wu; Changlin Hu
Journal:  Neurochem Res       Date:  2015-04-17       Impact factor: 3.996

Review 4.  Molecular mechanisms and cell signaling of 20-hydroxyeicosatetraenoic acid in vascular pathophysiology.

Authors:  Fan Fan; Ying Ge; Wenshan Lv; Matthew R Elliott; Yoshikazu Muroya; Takashi Hirata; George W Booz; Richard J Roman
Journal:  Front Biosci (Landmark Ed)       Date:  2016-06-01

5.  The revised human liver cytochrome P450 "Pie": absolute protein quantification of CYP4F and CYP3A enzymes using targeted quantitative proteomics.

Authors:  Scott Michaels; Michael Zhuo Wang
Journal:  Drug Metab Dispos       Date:  2014-05-09       Impact factor: 3.922

Review 6.  Cytochrome P450 ω-Hydroxylases in Inflammation and Cancer.

Authors:  Amanda L Johnson; Katheryne Z Edson; Rheem A Totah; Allan E Rettie
Journal:  Adv Pharmacol       Date:  2015-06-27

7.  Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection.

Authors:  Neha Sehgal; Kanhaiya Lal Kumawat; Anirban Basu; Vijayalakshmi Ravindranath
Journal:  PLoS One       Date:  2012-04-13       Impact factor: 3.240

8.  Adipocyte-specific deletion of HuR induces spontaneous cardiac hypertrophy and fibrosis.

Authors:  Adrienne R Guarnieri; Sarah R Anthony; Anamarie Gozdiff; Lisa C Green; Salma M Fleifil; Sam Slone; Michelle L Nieman; Perwez Alam; Joshua B Benoit; A Phillip Owens; Onur Kanisicak; Michael Tranter
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-05-21       Impact factor: 5.125

Review 9.  Systemic inflammation and microglial activation: systematic review of animal experiments.

Authors:  Inge C M Hoogland; Carin Houbolt; David J van Westerloo; Willem A van Gool; Diederik van de Beek
Journal:  J Neuroinflammation       Date:  2015-06-06       Impact factor: 8.322

10.  Thromboxane A2 receptor antagonist SQ29548 reduces ischemic stroke-induced microglia/macrophages activation and enrichment, and ameliorates brain injury.

Authors:  Aijuan Yan; Tingting Zhang; Xiao Yang; Jiaxiang Shao; Ningzhen Fu; Fanxia Shen; Yi Fu; Weiliang Xia
Journal:  Sci Rep       Date:  2016-10-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.